Aeglea’s Rare Disease Asset Succeeds At Phase III, In Line To Become First Product
BLA Filing Expected Next Year
The firm’s lead candidate has shown promise in a pivotal rare disease study, setting it on track for an upcoming BLA catalyst which could lead to Aeglea’s first approved product.
